Search results
Added:
1 week ago
SGLTi and GLP-1 in HF
Added:
10 months ago
Review Article
Added:
1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Added:
10 months ago
HRS 25 - TRANSFORM-AF shows patients with atrial fibrillation and obesity treated with a GLP-1 RA experienced a reduction in atrial fibrillation (AF)-related events.We are joined by Dr Varun Sundaram (Case Western Reserve University, US) to discuss the findings from the TRANSFORM-AF Study, which aimed to determine whether GLP-1 RAs could reduce the burden of AF in patients with both AF and…
View more
Added:
5 months ago
EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and…
View more
Added:
10 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that…
View more
Added:
1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the…
View more
Added:
8 months ago
Findings from a retrospective trial show GLP-1 medications for moderate peripheral artery disease (PAD) significantly decreased the risk of amputations.Dr Catherine Go (Charleston Area Medical Center, Charleston, WV, US) joins us to discuss outcomes from the largest retrospective trial evaluating the impact of GLP-1 medications for patients with moderate PAD. The study used the TriNetX database…
View more
Added:
10 months ago